KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Free Cash Flow (2016 - 2025)

Inovio Pharmaceuticals' Free Cash Flow history spans 16 years, with the latest figure at -$21.6 million for Q3 2025.

  • For Q3 2025, Free Cash Flow rose 22.52% year-over-year to -$21.6 million; the TTM value through Sep 2025 reached -$89.1 million, up 19.87%, while the annual FY2024 figure was -$104.6 million, 16.14% up from the prior year.
  • Free Cash Flow for Q3 2025 was -$21.6 million at Inovio Pharmaceuticals, down from -$20.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$19.7 million in Q4 2024 and bottomed at -$78.2 million in Q2 2021.
  • The 5-year median for Free Cash Flow is -$32.3 million (2023), against an average of -$38.5 million.
  • The largest annual shift saw Free Cash Flow tumbled 187.81% in 2021 before it soared 56.91% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$37.5 million in 2021, then rose by 4.97% to -$35.6 million in 2022, then increased by 26.28% to -$26.3 million in 2023, then grew by 25.16% to -$19.7 million in 2024, then decreased by 10.06% to -$21.6 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Free Cash Flow are -$21.6 million (Q3 2025), -$20.8 million (Q2 2025), and -$26.9 million (Q1 2025).